Latest / CME Outfitters Medical Education / Implementation and Access in Global HIV Care
Transcript
- 0:01SPEAKER_03: Hello and welcome.
- 0:02SPEAKER_03: On behalf of CME Outfitters, I'd like to welcome you and thank you for joining us.
- 0:07SPEAKER_03: This activity is titled Implementation and Access in Global HIV Care.
- 0:12SPEAKER_03: This program has been supported by an independent educational grant from Gilead Sciences, Inc.
- 0:20SPEAKER_03: Today's activity may include discussion of products or uses that are not approved by the FDA or other relevant regulatory authorities.
- 0:28SPEAKER_03: Faculty will identify investigational or off-label uses when discussed.
- 0:33SPEAKER_03: Reimbursement, public funding, and access pathways vary by country and change frequently.
- 0:39SPEAKER_03: Please consult current local or national guidance.
- 0:46SPEAKER_03: Here is our AI disclosure.
- 0:51SPEAKER_03: I'm Dr.
- 0:52SPEAKER_03: Oni Blackstock.
- 0:53SPEAKER_03: I'm a US-based HIV physician and researcher and founder of Health Justice, a research and consulting organization.
- 1:00SPEAKER_03: Prior to my current role, I led New York City's HIV response.
- 1:04SPEAKER_03: I'm delighted to be joined by three colleagues who bring global perspectives and insight.
- 1:12SPEAKER_03: Doctors Barber, Becker, and Lee, would you please introduce yourselves and provide a little bit about your background in HIV, starting with Dr.
- 1:20SPEAKER_03: Barber.
- 1:21SPEAKER_03: And after our formal introductions, we'll switch to first names throughout this presentation.
- 1:25SPEAKER_04: So thank you so much.
- 1:28SPEAKER_04: I'm Tristan Barber.
- 1:30SPEAKER_04: I'm a consultant in HIV medicine working at the Rural Free Hospital in London in the UK, an honorary associate professor at the Institute for Global Health at University College London.
- 1:41SPEAKER_04: I've been working in HIV care for just over 24 years, and we have a specialization at the Rural Free in looking after older people with HIV with a lot of complexity.
- 1:51SPEAKER_04: So people with HIV as they're aging.
- 1:54SPEAKER_04: And I'll hand over to Dr.
- 1:55SPEAKER_04: Becker.
- 1:57SPEAKER_06: Thank you so much, Tristan.
- 1:59SPEAKER_06: I'm Lindegail Becker.
- 2:00SPEAKER_06: I'm an infectious diseases specialist, professor of medicine at the University of Cape Town, and I'm director of the Desmond Tuto HIV Center and the CEO of the Desmond Tuto Health Foundation.
- 2:13SPEAKER_06: We are research organizations based here in Cape Town, South Africa, but I have been providing care, treatment, prevention, and other support for people living with and affected by HIV and tuberculosis and other related infectious diseases for more than 30 years.
- 2:33SPEAKER_06: So I've been around the block, Tristan.
- 2:35SPEAKER_06: But just to say that the work uh in the you know the last couple of decades has been extraordinary in terms of uh providing differentiated uh care, uh really moving innovation forward.
- 2:52SPEAKER_06: And uh it's it's a great pleasure to be on the program today.
- 2:57SPEAKER_06: And it's my chance now to hand over to Dr.
- 2:59SPEAKER_06: Tili.
- 3:03SPEAKER_05: Hi, I'm Dr.
- 3:04SPEAKER_05: Linghuali.
- 3:05SPEAKER_05: I'm the director of infection disease center in Guangzhou Ace People's Hospital, uh Guangzhou Medical University.
- 3:12SPEAKER_05: Uh, we are caring for and falling out nearly 18,000 HIV infected patients who have received AIT, providing them with a full management throughout the process.
- 3:25SPEAKER_05: Wonderful, thank you.
- 3:26SPEAKER_03: Thank you to our panelists.
- 3:28SPEAKER_03: So, to frame today's discussion, let's review our learning objective, which is to adopt workflows that include patient counseling, shared decision making, and interprofessional collaboration for routine care for patients with HIV.
- 3:45SPEAKER_03: So, before we get into the strategies themselves, I want to ground this discussion in what actually matters most, and that's the perspective of someone with lived experience of HIV care.
- 3:57SPEAKER_03: Rafe Zarazzi was diagnosed with HIV and with AIDS a week later on his 27th birthday.
- 4:04SPEAKER_03: In the year since, he's become a competitive bodybuilder and an outspoken advocate, using his platform to talk openly about HIV treatment, mental health, and what it means to live undetectable.
- 4:18SPEAKER_02: I think clinicians can help empower patients by really listening to the patient and staying engaged, asking questions about their life and getting to know them as individuals as their circumstances inevitably change.
- 4:34SPEAKER_02: And every member of the care team has a role in helping ensure that patients have access to information, that they have the tools at their disposal, the answers to the questions that they might have, so that the patient can make a truly informed decision and achieve the best health outcomes for them throughout their whole journey.
- 4:57SPEAKER_03: What Rafe is describing, being heard, being an active partner, it's the foundation of this entire program that it's built on.
- 5:06SPEAKER_03: And shared decisions we know are built on a foundation of trust, and that trust has layers.
- 5:12SPEAKER_03: At the base is competency and reliability.
- 5:16SPEAKER_03: Patients believe their clinician makes accurate diagnoses and consistently follows through.
- 5:22SPEAKER_03: Next is caring, community, and respect.
- 5:25SPEAKER_03: So patients again feel seen and heard, and then clarity and transparency, where patients know what, why, and how their clinician takes the steps that they're taking.
- 5:36SPEAKER_03: And at the peak, trust where provider and patients align on a plan and both are seen as part of ongoing shared decisions.
- 5:45SPEAKER_03: And so that's the scaffolding on which our discussion sits.
- 5:52SPEAKER_03: And now let's begin with an audience response question.
- 5:56SPEAKER_03: What challenges does your team face most when delivering routine HIV care consistently?
- 6:22SPEAKER_03: Okay, now let's dive right in and see how that plays out differently, depending on where you practice.
- 6:31SPEAKER_03: So each of our four regions faces a different version of the same problem.
- 6:36SPEAKER_03: So let's walk through what that looks like on the ground, starting here in the United States, where I'm based.
- 6:42SPEAKER_03: In the US, the issue isn't simply whether testing is available, but whether testing, prevention, and treatment are connected seamlessly and efficiently.
- 6:53SPEAKER_03: Reducing delays in our initiation, building trust, and incorporating patient choice and agency are important components of that workflow.
- 7:04SPEAKER_03: So, Tristan, how does that compare to what you are seeing in the UK?
- 7:10SPEAKER_04: So the UK has increasingly and particularly recently used nationally supported opt-out testing approaches, including in our emergency departments, with linkage into sexual health prevention and HIV services.
- 7:25SPEAKER_04: The remaining challenge can be translating guidance into routine clinician practice, particularly when conversations involve key populations.
- 7:35SPEAKER_06: Linda Gill, how about you?
- 7:38SPEAKER_06: So, Oni, I'm based in South Africa, and of course, um viewers might know that we have the biggest HIV burden of any country in the world.
- 7:48SPEAKER_06: We also have the biggest treatment program, um, and we're trying to develop a very big prevention program.
- 7:54SPEAKER_06: Um, so it really comes down to scale for us.
- 7:57SPEAKER_06: It's a generalized epidemic.
- 7:59SPEAKER_06: Um, and I guess needs must, we have really developed a number of differentiated tools to just deal with large numbers of people.
- 8:08SPEAKER_06: Um, the clinic that I run, you know, has initiated upwards of 20,000 people on antiretrovirals.
- 8:16SPEAKER_06: Um, but we have pockets of of types of populations or individuals who are more vulnerable than others.
- 8:24SPEAKER_06: And here, for example, and I think this is true for the for a large part of eastern southern Africa, are um important populations such as the LGBT population, people who are young, uh, people who um do not routinely access care, such as cisgender, heterosexual men in our in our setting, and of course, people with coinfection uh such as tuberculosis.
- 8:53SPEAKER_06: And this is where peer and community-based um uh interventions really come into their own.
- 9:00SPEAKER_06: And so we have really encouraged moving out of facilities and into communities to make sure we get closer to the kinds of populations that I consider key populations.
- 9:11SPEAKER_06: The definition for me are those people are most vulnerable to HIV but are least likely to access the traditional or you know government services as they exist today.
- 9:22SPEAKER_03: Yes, thank you, Linda Gail.
- 9:24SPEAKER_03: And Ling Hua, how about in China?
- 9:26SPEAKER_03: What do things look like there?
- 9:29SPEAKER_05: Yeah, in China, I think a stigma of influence of the people uh disclose their HIV status to family, their friends or colleagues, um, which can affect the support and engagement in care.
- 9:46SPEAKER_05: Um, in addition, and some patients receiving a non-cost, uh, that's a free cost uh if everyone developing or AZ-based regimens, uh, which may appear in their collaborative challenges, and this will uh affect their uh hearing.
- 10:07SPEAKER_05: Specialized hospital-based care, uh P support and uh digital uh flat form uh can help address some of these barriers.
- 10:18SPEAKER_05: Uh, but I think um we are following up this more than uh the 17,000 patients.
- 10:25SPEAKER_05: Uh, we have a lot of work uh to care for them, uh but uh we don't have uh much time uh to look up after all of their needs.
- 10:35SPEAKER_05: Yeah.
- 10:36SPEAKER_03: Thank you so much for everyone for sharing your unique context.
- 10:40SPEAKER_03: Uh so next we're going to take a moment for another audience response question.
- 10:46SPEAKER_03: Which strategy do you would do the most to expand your team's capacity for routine HIV care?
- 11:12SPEAKER_03: Well, whatever you picked, the honest truth is that uh every one of those strategies runs into sort of the same challenges, and that's resources.
- 11:20SPEAKER_03: Um let's talk about uh the resource limitations and the global funding landscape that's shaping what's actually possible in each of our settings.
- 11:29SPEAKER_03: And we'll start with Dr.
- 11:31SPEAKER_03: Li with Linghua, um, and then our other panelists will chime in.
- 11:35SPEAKER_03: So, Linghua in China, can you share with us what you're seeing?
- 11:40SPEAKER_05: Um in China, uh the physicians uh have very uh just limited access to global HI funding uh mechanisms.
- 11:50SPEAKER_05: Um, our programs uh rely mainly on the national research grounds rather than the international funding uh students at the region depend on, and we have um some uh medicines.
- 12:05SPEAKER_05: Thank you.
- 12:08SPEAKER_06: Well, of course, we're right in the midst of the so-called funding crisis in terms of uh PEPPAR-related countries, and we've also seen downturns in in global fund um funding to countries and the quantity or the volume of funding that is coming through.
- 12:27SPEAKER_06: So this is having a real impact.
- 12:29SPEAKER_06: And here in South Africa, we you know we actually proportionately get one of the biggest grants, or we're getting the biggest grants from PEPFA, although that only makes up one-fifth of our response.
- 12:40SPEAKER_06: So, in some ways, we're lucky.
- 12:42SPEAKER_06: The basic antiretrovirals for both treatment and prevention are provided by the government in our public sector.
- 12:50SPEAKER_06: Um, but it's the it's those very important add-ons: data collection, uh supporting people in communities, reaching the key populations, finding people who have cycled out of care, all of that, the sort of fourth 90 stuff, um, you know, the the aspects that really add to the quality of our programs, that is what is very much at risk.
- 13:16SPEAKER_06: Um, and we're starting to see some, you know, and I think the recent conference uh in Rio really started to underpin some of that.
- 13:24SPEAKER_06: We're starting to see gaps in testing, and we're certainly starting to see more people coming in with advanced HIV.
- 13:31SPEAKER_06: So uh I think a difficult time and certainly underlining the need for resources to ensure quality in our programs.
- 13:39SPEAKER_03: Uh Tristan, um, so just on to you, what type of barriers are you seeing?
- 13:46SPEAKER_04: Thanks so much.
- 13:46SPEAKER_04: I think uh in the UK and across Europe the pressure looks very different.
- 13:50SPEAKER_04: Certainly in the UK we have a free at the point of access healthcare system, so everyone with HIV is entitled to free treatment and care.
- 13:59SPEAKER_04: What we do see increasingly, though, I think, is a lot of funding being focused on prevention, being focused on testing, and some of the story of people who've lived for many decades with HIV being forgotten, a real assumption that they're living a normal life when actually their life has been completely altered by the duration of their HIV infection.
- 14:19SPEAKER_04: So perhaps less funding at the other end, uh, if you like, in terms of improving quality of life and around medical complexity as people age.
- 14:27SPEAKER_04: So it's less about the hardware and more about the software, if you like, the care quality and also fragmentation across different services.
- 14:36SPEAKER_03: Yes, yes.
- 14:36SPEAKER_03: Okay, so very different funding realities and different regions and also like experiences for people living with HIV navigating these systems.
- 14:45SPEAKER_03: Um but what we'll do is we'll see that there are some common workflow strategies that may be able to help stretch the resources that are available.
- 14:55SPEAKER_03: So across all four of our regions, um, there are four workflow strategies that keep coming up as ways to expand HIV care capacity without necessarily adding staff.
- 15:08SPEAKER_03: And so I'll just walk through this briefly through this slide about what each practice looks like.
- 15:13SPEAKER_03: So differentiated service delivery means adapting service intensity to patient need.
- 15:20SPEAKER_03: So you'll see stable patients getting fewer or faster visits, thinking about multi-month dispensing, um, adherence support groups, fast track refills, and the like.
- 15:32SPEAKER_03: Next is decentralized care, which means moving people who are stably on treatment out of specialist clinics and into primary care and community sites.
- 15:44SPEAKER_03: So for instance, nurse-led anti-retroviral treatment in primary care, community pickup points, mobile clinics, so reaching people where they are.
- 15:53SPEAKER_03: And then next is task shifting.
- 15:55SPEAKER_03: Task shifting means shifting defined tasks to train support staff who can safely do them.
- 16:02SPEAKER_03: So thinking about nurse-initiated anti-retroviral therapy treatment, um, pharmacist refills, uh, community health workers, um, doing counseling, peer navigators.
- 16:14SPEAKER_03: And then lastly, co-located services, which means combining HIV care with other services that patients also need.
- 16:23SPEAKER_03: So this could be if they're receiving treatment also for tuberculosis, they can receive that together with their HIV care for mental health, antenatal care, and other chronic diseases, as Dr.
- 16:36SPEAKER_03: Barbara was mentioning, that are becoming increasingly prevalent as we see people with HIV living longer.
- 16:43SPEAKER_03: So for our learners, let's begin to think about how long-acting injectable treatment administered over uh every two or six months would shift your workflow.
- 16:54SPEAKER_03: Linda Gale, could you talk us through two solutions that you have implemented in practice, um, community-based and peer-supported care, as well as multi-month dispensing?
- 17:07SPEAKER_06: Yes, thanks.
- 17:08SPEAKER_06: Um, you know, so we are an entire our public sector ARV and prevention program is entirely nurse-run.
- 17:16SPEAKER_06: So we've already done that switch to, you know, it's primary health level and it's nurse-run.
- 17:22SPEAKER_06: But uh, and a number of those great ideas you put out there, we have implemented in the public sector in South Africa.
- 17:29SPEAKER_06: But I will highlight two of those.
- 17:31SPEAKER_06: The one is the terrific adherence club approach, which is run almost entirely by uh community healthcare workers who are seen as peer supporters, um, many of them living with HIV themselves, they're in the community and helping other people uh either come to adherence clubs to pick up their medication or just to adhere to their medication on a regular basis.
- 17:56SPEAKER_06: And these folk become really experts.
- 17:59SPEAKER_06: Um, you know, they are patient experts and they they become they have huge credibility because they're very knowledgeable and it's a great task shifting uh strategy.
- 18:10SPEAKER_06: The other one is, and this really came to the fore during COVID, um, where we went from, you know, at least the three-monthly multi-month dispensing to six-monthly multi-month dispensing.
- 18:22SPEAKER_06: So it really starts to make it equivalent to some of our longest um antiretroviral uh injectable formulations.
- 18:30SPEAKER_06: Does mean people have to walk out with those rattling bottles, uh, but they can walk out with all the rattling bottles so they don't have to come back for up to six months.
- 18:41SPEAKER_06: Now there are some legalities there, we're not allowed to always prescribe more than six months at a time, uh, but it does hugely unburden people and it definitely does simplify care and it definitely aids people to be adherent because some of the biggest costs are not only transport costs and money costs, but their time costs.
- 19:03SPEAKER_06: Um, and so this really does unburden people terrifically.
- 19:07SPEAKER_06: Thanks.
- 19:07SPEAKER_03: Wonderful.
- 19:08SPEAKER_03: Thank you, Linda Gail.
- 19:09SPEAKER_03: Um, that definitely shows how you can stretch capacity when you don't have more staff to add and also make things easier for our patients.
- 19:16SPEAKER_03: Uh so Tristan, the UK has taken a different route to the same goal.
- 19:21SPEAKER_03: Could you walk us through uh the UK pathway?
- 19:25SPEAKER_04: We've had real success in the last four years or so by implementing an opt-out scheme for testing for bloodborne viruses in our emergency departments.
- 19:34SPEAKER_04: Uh, this started in England, is also now rolling out to Scotland.
- 19:38SPEAKER_04: So people have posters in the emergency department when they attend that tell them they're going to be tested for treatable bloodborne viruses.
- 19:45SPEAKER_04: They have the option to opt out, but essentially anyone that's requiring a blood draw will have their blood automatically tested for HIV, hepatitis C, and hepatitis B.
- 19:56SPEAKER_04: And most people do this through automated order sets so the person taking the blood doesn't even have to think about requesting the test.
- 20:04SPEAKER_04: Our laboratories then highlight the reactive or positive tests.
- 20:08SPEAKER_04: In our case at the Rule Free Hospital, they do this to our nursing team in the HIV service who look at the results.
- 20:15SPEAKER_04: They recall people for confirmatory testing, and if they're confirmed to be living with HIV, they're rapidly engaged into HIV care and treatment.
- 20:25SPEAKER_04: We also have community uh workers and coordinators who can help try and contact people who've had a reactive result who don't respond to attempts to contact them.
- 20:34SPEAKER_04: In addition, we may contact their primary care physician if we feel that it's really important that they're seen soon.
- 20:41SPEAKER_04: And we also have peer support workers.
- 20:43SPEAKER_04: Uh, we now have money funded by the UK government to support peer support in this process so that peer support workers, people with lived HIV experience, can contact the person with a new diagnosis very early on and make sure that they have that support in addition to the medical nursing and other multidisciplinary team support they have within an HIV service.
- 21:03SPEAKER_04: So it is working really well.
- 21:05SPEAKER_03: That's really wonderful.
- 21:06SPEAKER_03: And I'm hearing some overlap, including uh the role of peers with what Linda Gale also shared.
- 21:13SPEAKER_03: Um and so that's a great segue to think about in this work that you are doing, uh, what are what are some of the sort of the biggest structural barriers that you're seeing for um people living with HIV getting to care?
- 21:27SPEAKER_04: So I think what's been interesting is that through the CD Oct Out scheme, we're seeing the demographics of people who are receiving a new diagnosis completely changing.
- 21:36SPEAKER_04: You know, these aren't people from traditionally high-risk groups who've opted in to coming and seeking an HIV test.
- 21:43SPEAKER_04: They're people for whom it comes completely out of the blue.
- 21:46SPEAKER_04: And what we're also seeing in Europe uh and in the UK is that access varies widely between metropolitan and rural areas.
- 21:54SPEAKER_04: Our areas of highest prevalence have been in big cities, and these get the investment.
- 22:00SPEAKER_04: And what we're now seeing is that in rural areas, traditionally where the prevalence was the was lower, actually the untested prevalence, the untested proportion rather, is actually increasing and the amount of late diagnosis is increasing.
- 22:14SPEAKER_04: And even in the UK, there are some areas where you know people may take three or four hours to reach their clinic, certainly in some rural parts of Scotland, and lower prevalence areas may have simply fewer HIV services, which increases the travel access and cost burden for individuals.
- 22:31SPEAKER_04: So income and transportation are two of the most consistent structural barriers we see.
- 22:36SPEAKER_04: And I guess that does hold true across many different regions.
- 22:39SPEAKER_06: Tristan, I think just terrific.
- 22:41SPEAKER_06: Congrats, you know, that the UK has has done this.
- 22:44SPEAKER_06: I think it's it's eye-opening and so important.
- 22:48SPEAKER_06: I think this is the challenge, right?
- 22:50SPEAKER_06: Really reaching those individuals who are hard to reach in terms of geography, um, and then hardly ever reach simply because our systems are are just not geared towards them.
- 23:03SPEAKER_06: And I think this has been shown repeatedly that uh if people don't have money for transport, uh they you know they just won't be able to come in for care.
- 23:11SPEAKER_06: And this is where I think some of these strategies to take care to them uh is are are just so important.
- 23:18SPEAKER_06: And you know, again, I think we've seen wonderful examples in Africa of people having their antiretrovirals delivered in motorbikes, um, on drones, uh, you know, uh and and I think this is where we center the need to get the treatment to to the individual, um, almost regardless, um, and to make it as simple for people to adhere and to stay within the program.
- 23:44SPEAKER_06: Um, of course, the less frequently dosed um brings a whole nother paradigm to this, and and I think this is really going to change the face of antiretroviral delivery in in the future.
- 23:57SPEAKER_06: But um I think in the meantime, these differentiated models are so important to overcome things like transport costs.
- 24:06SPEAKER_03: Wonderful, thank you.
- 24:06SPEAKER_03: Yeah, hearing a lot of um similarities and a lot of creativity also.
- 24:10SPEAKER_03: Um, okay, so we're moving on for yet another audience response question.
- 24:16SPEAKER_03: Um, this one asks, which workflow gap most limits your team's ability to integrate comprehensive comorbidity care into routine HIV visits?
- 24:47SPEAKER_04: So I think the results are really interesting.
- 24:49SPEAKER_04: What we see in the UK is that people are limited in terms of providing integrated, comprehensive comorbidity care because they don't feel skilled to provide treatment for the comorbidities that they identify.
- 25:01SPEAKER_04: So sometimes people may be frightened about even screening for a comorbidity because they don't know what they're going to do next.
- 25:07SPEAKER_04: And what I will often say to an individual is, I'm very happy to help you coordinate some of the complexity of your care, but I may not be the right person to provide treatment for your comorbidity.
- 25:19SPEAKER_04: So I do need you to allow me to engage with your primary care physician or other specialists to make sure that you get the best integrated care for your comorbidities, particularly as you're getting older.
- 25:30SPEAKER_04: I want to do the right thing, but I may not be the right person to provide the care for that individual, even though they trust their HIV service and sometimes their HIV clinician more than they trust other providers.
- 25:42SPEAKER_04: So it's about providing coordination, reassuring them, gaining their trust and consent, and then involving other professionals that who are more skilled to provide the care for the complex comorbidities that you identify.
- 25:55SPEAKER_03: So let's talk about uh additional strategies for structuring resources to help expand access to HIV care.
- 26:02SPEAKER_03: And we'll start with Linda Gale and then we'll move on to Linwa.
- 26:08SPEAKER_06: Yeah, and I think this is a time when we really are being asked to do much more with less, um, and and so really calling for those efficiencies.
- 26:18SPEAKER_06: But I really want to, and I know that my fellow panelists here feel as strongly as do you, Oni, that we don't give up on quality of care by finding those efficiencies.
- 26:30SPEAKER_06: I do want to point out that, you know, and I know that large parts of the world are now moving to nurse-driven services, but just underpin that really task shifting to nurses in the first instance and then to peers to lay healthcare workers is uh very, very effective, very feasible, very acceptable, um, and highly uh you know cost saving.
- 26:57SPEAKER_06: So uh we years ago did actually did a uh an NIH funded um research prep project to say, can nurses give antiretrovirals?
- 27:08SPEAKER_06: And I'm talking the early 2000s here.
- 27:10SPEAKER_06: Can nurses give antiretrovirals as safely and effectively as doctors?
- 27:14SPEAKER_06: And and I'm pleased to say maybe it's a no-brainer, but we did show the research that this is you know absolutely fine.
- 27:21SPEAKER_06: And and um and and for those programs where you know medical clinicians have just not wanted to give up the job, um, I think it is really important to note that often this is done more effectively and done well by peer navigators who who, as has already been said here, often understand the situation better, often are more on hand, have more time.
- 27:45SPEAKER_06: Um, and so that really I think is one of the most effective ways to save resources and save costs.
- 27:52SPEAKER_05: Okay, um, China's model uh looks a little different, and the care uh stays a central ofin hospital and the city designated uh facilities and our uh national uh 4-3 and one care uh strategy.
- 28:11SPEAKER_05: Um, that's the AIT policy.
- 28:13SPEAKER_05: And doctors and the nurses work together uh to help uh these patients, and we do have the uh the just the case manager uh to help the patients.
- 28:25SPEAKER_05: Um and the patients are generally um shifted out to uh other uh uh providers, uh the way you have seen uh in the task shifting model.
- 28:37SPEAKER_05: But we do, um if the patient uh he or she wants to shift to another uh designated hospital, we have the uh the help to help them uh to uh shift to another.
- 28:51SPEAKER_05: It's very freely, they can just shift to another designated hospital, uh, but we will uh record it in the system, and then the patient will not be uh lost, lost.
- 29:04SPEAKER_05: Uh that that's very important uh because uh we have the patient loading in the uh manage uh in the management and uh and the treatment, but if they are lost and we will not know uh they have uh taken the medicine or not.
- 29:20SPEAKER_05: Yeah, so that's the uh different, a little different.
- 29:23SPEAKER_05: Okay, okay.
- 29:24SPEAKER_03: Great, thank you, Linghua.
- 29:26SPEAKER_03: So yeah, so we heard that different ways of staffing uh are one way to extend reach and technology is another.
- 29:32SPEAKER_03: So um let's talk a little bit about uh the digital tools that support adherence and engagement and HIV care, and then I'll wrap up with some brief data about the accelerate model uh from the recent um AIDS 2026 conference.
- 29:49SPEAKER_06: Maybe I'll I'll jump in first here, Oni, that um it's you know, there's uh what we find is companions in the pocket can be incredibly useful, uh both to disseminate information, um, and it's really important that our patients, our clients get good information to make good choices and to know uh what is the best path for themselves.
- 30:13SPEAKER_06: Um and I'm just gonna highlight one using a voice response system, it actually comes out of Uganda, but I think it's important not only to speak about South Africa, lots of innovation coming out of the African continent.
- 30:25SPEAKER_06: Uh, this is called Call for Life, um, and they've published data on how this uh digital tool helps particularly young people adhere better to their anti-retrovirals, and we know this is a population we really do want to provide support for to stay on their stay in the program and stay on the anti-retrovirals in a consistent way.
- 30:47SPEAKER_06: So, you know, uh it is published, people can go and look it up.
- 30:51SPEAKER_06: Um, but I think more and more we're seeing these digital tools either as a one-way uh you know uh direction to provide information, but also even better, a two-way direction, uh, where people can actually ask questions or engage in our with with a chat system um and and and thereby get supported, not only in terms of the adherence, but also often on a mental health front um with other difficulties in their lives.
- 31:21SPEAKER_06: So, you know, I think this space is one that is going to expand um and and looking forward to seeing it as well as another way to to save costs.
- 31:32SPEAKER_05: Um Ling Hua, how about in China?
- 31:37SPEAKER_05: In China, uh we use a lot of the digital tools to uh to help our patients, and we have a really a very good internet.
- 31:46SPEAKER_05: Um and we uh always use the uh the song APP and uh and the VCA.
- 31:52SPEAKER_05: Uh that's the communication, uh easy communication uh for people uh to communicate.
- 31:59SPEAKER_05: Um so we can use that uh to um just um uh get these um uh patients uh to uh improve their adherence and uh we provide with some on the commodity and management in the same hospital, and then the patient uh don't need to go other uh hospital or go to other departments to see uh some uh just uh the uh the kidney uh problems uh kidney um that disease and other uh disease, and then uh the patient will uh get uh just go to the one clinic and uh get all the uh that the disease is solved at the same time.
- 32:45SPEAKER_05: Yeah.
- 32:47SPEAKER_04: Thank you so much.
- 32:47SPEAKER_04: I'll jump in if I may, thanks, Oni.
- 32:49SPEAKER_04: Uh I think in the UK what we've seen is a lot of red tape sometimes that holds us back.
- 32:55SPEAKER_04: Uh, a lot of fear about data sharing using technology, both from service users and also from providers.
- 33:02SPEAKER_04: And what we see is some clinics moving ahead much faster with the use of AI and digital technology.
- 33:09SPEAKER_04: Some clinics are using the Emerge smartphone-supported HIV care pathway to help with adherence and re-engagement.
- 33:16SPEAKER_04: Chelsea and Westminster developed their own platform called CLIC to help patients get clinic ready before their appointment.
- 33:23SPEAKER_04: At my own hospital, we had some funding to develop an app to support patients in that way.
- 33:27SPEAKER_04: And unfortunately, it was blocked by our trust because it didn't align with their IT policy, which was a little bit frustrating.
- 33:34SPEAKER_04: So we were trying to do something for people with HIV that got blocked.
- 33:38SPEAKER_04: And as a consequence, at the British HIV Association, we've established an AI and digital working group to try and look at where some of the inequities might exist around the country in terms of the rollout of this technology.
- 33:50SPEAKER_04: But I think it's also important to say that it might support not only uh adherence and re-engagement, but can also really help people with managing complex comorbidities uh as they get older.
- 34:01SPEAKER_04: So I think there are a lot of opportunities for the use of this technology, but variable acceptance by people living with HIV and varying acceptability perhaps by different healthcare systems about how to integrate this with their other existing systems.
- 34:16SPEAKER_03: Yes, all very exciting.
- 34:17SPEAKER_03: And I think that point around how acceptable it is to patients is critically important.
- 34:23SPEAKER_03: And so ensuring that they're at the table when these technologies are being tested out is so important.
- 34:28SPEAKER_03: Um, and so I'm also happy to uh share about um an implementation study that was done looking at a telehealth-enabled rapid art reinitiation and relinkage to care model.
- 34:41SPEAKER_03: The study was called Accelerate.
- 34:42SPEAKER_03: Um, it was presented at AIDS 2026.
- 34:45SPEAKER_03: Um, and it showed um benefits, including decreases in viral suppression, increases in adherence, as well as improvements in patient reported outcomes.
- 34:56SPEAKER_03: So I think lots of great potential and innovative interventions to come.
- 35:02SPEAKER_03: Um, so now we are going to delve into um acting injectable treatment logistics and workflow aspects across regions, and we're going to get our panelists' um sort of experience with that.
- 35:14SPEAKER_03: So, Linda Gail, why don't we start with you in South Africa?
- 35:19SPEAKER_06: Yeah, thanks.
- 35:20SPEAKER_06: So, South Africa often the um the place where phase three studies happen, right?
- 35:25SPEAKER_06: So we have tested all the long-acting treatments and we certainly have tested all the long-acting prevention uh modalities, pre-exposure prophylaxis.
- 35:36SPEAKER_06: Uh, we're doing better in terms of access to the long-acting pre-exposure prophylactics, but the treatment unfortunately has stalled.
- 35:44SPEAKER_06: And the reason for this is that um the the current long-acting agents are and they are licensed in our country, are uh the two-monthly Caboteg River with Raw Pivory.
- 35:57SPEAKER_06: And unfortunately, this has not been commercialized and it has not been rolled out in the public sector.
- 36:05SPEAKER_06: Um, in in as far as I know, in any country, unfortunately, in the southern hemisphere.
- 36:12SPEAKER_06: Um, this is partially because the the company that should have commercialized decided not to do so.
- 36:19SPEAKER_06: Um, and so we are watching with a great deal of bated breath as other countries to the north of us are beginning to roll out long-acting agents.
- 36:31SPEAKER_06: We have participated in a number of implementation signs, phase three Bs, um, etc., throughout the continent.
- 36:39SPEAKER_06: So people will have heard about a study called CAES, a study called uh Impala.
- 36:45SPEAKER_06: We are going to see the LATA study come through.
- 36:48SPEAKER_06: We did a study called Affinity in Adolescence, all of them showing huge acceptability, a lot of excitement amongst patients and people, um, and very good outcomes in terms of adherence rates.
- 37:04SPEAKER_06: So there is no doubt that this long-acting option is definitely an answer for uh certain populations.
- 37:12SPEAKER_06: I believe adolescents can, particularly adolescents and young people whose lives are very busy and daily treatment, particularly those who've lived long with HIV, those people really rarely could benefit from long-acting uh treatment.
- 37:27SPEAKER_06: So we are, let me say, excited about when they do come.
- 37:33SPEAKER_06: We are always advocating for that.
- 37:35SPEAKER_06: We do recognize there is a downside.
- 37:37SPEAKER_06: And uh, you know, with multi-month dispensing, I've already noted that you can actually get your treatment for up to six months, um, and and that clearly is very useful.
- 37:47SPEAKER_06: Um, for some people, treatment can be courier, uh, you know, it can arrive in in a in the post box.
- 37:53SPEAKER_06: Uh, that definitely is not the case with injectables where people have to go to a clinic and have it administered by a nurse, but there's no doubt that the freedom that comes from getting your injection, be leaving and not having to worry about treatment is is huge.
- 38:10SPEAKER_06: There is obviously other kinds of long-acting treatment coming.
- 38:14SPEAKER_06: We saw some exciting data um at uh again at Rio.
- 38:19SPEAKER_06: Uh, so I think this space is is one that we really are very excited about.
- 38:23SPEAKER_06: I'm just concerned that again, here in Africa, access is often due to the fact that these treatments cost uh and our government simply can't afford them.
- 38:37SPEAKER_03: Thank you, Linda Gail.
- 38:38SPEAKER_03: Linghua, how about in China?
- 38:40SPEAKER_03: What are you seeing in terms of availability of long acting injectables for treatment?
- 38:47SPEAKER_05: Yeah, um in China uh the long-acting uh injectable uh AIT has actually uh been approved to use in since uh 2023.
- 39:00SPEAKER_05: And uh many patients, yeah, I think some patients, yeah, uh possibly uh we have uh nearly 10,000 patients receive LAI up to now in China.
- 39:12SPEAKER_05: Um and it is uh it that means many patients like this treatment, yeah, this is a new treatment strategy, but the uptake is limited uh because of the cost, and uh I think um that's um every two months it um sounds uh too too much for them.
- 39:35SPEAKER_05: Yeah, if every two uh every three months, every six months it will be better for those patients.
- 39:41SPEAKER_05: Yeah, we'll attract um many more applications.
- 39:45SPEAKER_05: And because our career model is uh hospital-centralized and mentoring and monitoring this uh ingestion requires uh the close uh physician and the nurse coagulation, uh cooperation.
- 40:00SPEAKER_05: And so uh beyond the cost, uh our barriers are really uh just uh is about the severe arm capacity and the patient access.
- 40:11SPEAKER_05: Yeah, I think uh the lung uh um that's uh I think injectable um medicine is a very, very uh good one for those patients, uh, but we still need um that's the the better one.
- 40:24SPEAKER_05: Yeah, I I I'm looking forward to the every three months and every six months a lot, yeah.
- 40:31SPEAKER_03: Those are such great points.
- 40:33SPEAKER_03: And I'm hearing a lot of similarities as well, like to here in the United States, um, with the availability of long-acting injectables.
- 40:40SPEAKER_03: And I think it just speaks to the fact that something can be available, but if it's not accessible, um, you know, that's a huge um gap.
- 40:47SPEAKER_03: Um, and so we it's about closing that that space so folks can get access to these like really powerful and effective treatments.
- 40:54SPEAKER_03: Um, so anyway, here as mentioned before, um there are challenges in terms of uptake in more rural areas.
- 41:02SPEAKER_03: So in the deep south part of the United States, that's the current epicenter of the HIV epidemic.
- 41:09SPEAKER_03: Um, it's you know largely rural, and we're seeing um much lower uptake of long-acting injectables there.
- 41:16SPEAKER_03: And then just operationally, like in the clinics, it requires a lot.
- 41:20SPEAKER_03: Um, there's you know, insurance authorization, um, you know, staff have to create workflows to track appointments so that folks come back on time.
- 41:29SPEAKER_03: Um, lingois, you mentioned, you know, it's um clinician-administered um terms of the injection, uh figuring out you know what happens with mistosis.
- 41:39SPEAKER_03: Um, and so all of these uh play a role in addition to issues around um, you know, transportation, reimbursement staffing.
- 41:47SPEAKER_03: Tristan, what about in the UK?
- 41:50SPEAKER_04: Thank you.
- 41:50SPEAKER_04: Well, in the UK, in theory, long-acting injectables are available everywhere, but we know that different clinics have differential access due to resources, staffing, uh, ability to provide the injections, pretty similar to issues that other people are experiencing if they have access around the world.
- 42:09SPEAKER_04: Um, but we have built structured injection visit workflows to support injectable rollout where it is available.
- 42:15SPEAKER_04: Uh, we offer scheduling systems, reminder tools, and what we've really found in our own clinic is that although we do normally give six months of oral medication, people are asked at the moment to come in for visits every eight weeks.
- 42:28SPEAKER_04: The people with HIV who've chosen to have injections actually say that they really like the light touch contact they have with the nursing team in particular.
- 42:37SPEAKER_04: So I've seen people, you know, really smiling when they come into clinic about the huge change it's had on their overall health-related quality of life and their access to care and support.
- 42:47SPEAKER_04: So, our remaining barriers, like other places, um, are very much about service capacity, local policy variation, and making sure that access stays equitable across different patient populations.
- 43:02SPEAKER_03: Yes, thank you so much.
- 43:03SPEAKER_03: It's all great.
- 43:04SPEAKER_03: And I think uh, Tristan, as you were saying about um these frequent touch points, but sort of light touch points, um, just speaks to how important different members of the team are.
- 43:14SPEAKER_03: Um, and also it almost creates a more patient-centered um approach to care so that patients don't have to wait that time to have a conversation with a healthcare provider.
- 43:24SPEAKER_03: Um, so thank you all for sharing where your regions are with respect to long-acting treatment.
- 43:30SPEAKER_03: And it looks like there's some shared challenges in terms of capacities and cost limitation and availability.
- 43:37SPEAKER_03: Um, I'm gonna move on to uh the next slide, which is you know, speaks to how even when access and logistics are um solved, we there's still barriers and adherence still is something that remains a challenge.
- 43:54SPEAKER_03: And so I'm gonna touch on five barriers that have kept showing up in the evidence and also.
- 44:00SPEAKER_03: So in practice, and they all kind of interact with each other.
- 44:03SPEAKER_03: So stigma and fear of disclosure.
- 44:06SPEAKER_03: So whether someone feels safe being, you know, with their status being known is definitely a barrier we know to testing and to treatment and to prevention.
- 44:18SPEAKER_03: Structural and economic barriers play a role.
- 44:21SPEAKER_03: So cost and transportation and housing instability, life transitions and competing priorities.
- 44:28SPEAKER_03: So people have a lot going on in their lives and taking treatment might not be understandably as at the top of their list.
- 44:37SPEAKER_03: Provider preparedness and continuity of care.
- 44:40SPEAKER_03: So whether the person in front of them is equipped to support them consistently over time is really important.
- 44:47SPEAKER_03: We need to make sure providers are providing again patient-centered care.
- 44:51SPEAKER_03: And then lastly, a mismatch between what patients actually want and what's available to them.
- 44:59SPEAKER_03: And so we're just going to keep these in mind as we move into what actually helps.
- 45:04SPEAKER_03: So Tristan, can you provide some tips for how do we keep the door open for person-centered ART engagement?
- 45:14SPEAKER_04: Really happy to.
- 45:15SPEAKER_04: I think it all starts for me with not making assumptions about what individuals want.
- 45:20SPEAKER_04: I know when we first saw injectable rollout in the UK, I think we all assumed that we knew our patients who would want to go on to this treatment, and we knew the people that we thought wouldn't want to go on it.
- 45:32SPEAKER_04: And actually, I've seen myself find that that can be the exact reverse.
- 45:36SPEAKER_04: Someone who I thought was happy with six months of tablets, has a very busy life, will say, actually, this would be really liberating for me.
- 45:44SPEAKER_04: So I think not making assumptions, being non-judgmental, and having a holistic approach is really what's very important in terms of thinking about person-centred antiretroviral therapy.
- 45:55SPEAKER_04: So I think for clinicians and teams, that non-judgmental, open-ended communication about priorities and barriers, kind of folding adherence, side effects, comorbidities, and an individual's life circumstances into the routine visit are really essential.
- 46:12SPEAKER_04: It's really important to use simple language and educate and support people because otherwise you end up with differential care for people who have more agency, more health literacy, and can advocate most for what they want.
- 46:25SPEAKER_04: So you need to make sure you're explaining things clearly.
- 46:27SPEAKER_04: And when you've given key messages, you want people to give them back to you so you know they've understood the information you've provided.
- 46:34SPEAKER_04: And also you need to use your team, you need to use your multidisciplinary team.
- 46:38SPEAKER_04: So bring in pharmacists, nurses, counsellors, peer supporters or peer navigators when needed.
- 46:46SPEAKER_04: I think for wider systems, it's important to train teams in stigma-free communication.
- 46:52SPEAKER_04: You need systems in place that flag when someone has missed a visit, and you need refill gaps to be provided early.
- 47:00SPEAKER_04: You need oral bridging to be provided for those people who need oral bridging at the right time so that they can access that.
- 47:07SPEAKER_04: And you need clear referral pathways and where possible differentiated service delivery options for different individuals with different needs.
- 47:16SPEAKER_03: Oh wow, lots of great stuff.
- 47:18SPEAKER_03: So thank you, Tristan, for walking us through what keeps the door open for our ENR patients.
- 47:24SPEAKER_03: We also know that interprofessional collaboration is a big part of the work that we do in HIV care.
- 47:30SPEAKER_03: And so this diagram shows nurse-driven and community-supported collaboration in South Africa, more hospital-centered interprofessional collaboration in China, a more specialist or sexual health clinic-oriented approach in Europe.
- 47:47SPEAKER_03: And sort of we're seeing emerging task shifting models here in the US.
- 47:52SPEAKER_03: But we know whoever's available, the goal remains the same is that we want to ensure that the counseling is available, that workflows are matched, that shared decision making is happening to support our patients.
- 48:06SPEAKER_03: So we have spent this session walking through some frameworks and strategies and workflows built to fit different settings.
- 48:14SPEAKER_03: I want to close the same way with Angelina Namiba, who's been living with HIV for more than 20 years.
- 48:21SPEAKER_03: And Angelina's message is clear.
- 48:26SPEAKER_01: So for me, the three A's, as in access, acceptability, and adaptability are really important because when patients and clinicians have the shared collaboration of making decisions about their health and well-being, it means that the clinician is really able to treat the patient well because they have the full information.
- 48:44SPEAKER_01: It means they are listening to what the patient needs.
- 48:47SPEAKER_01: But also the patient gets the best out of the healthcare provider and clinical care, which then equates to good quality of life for the patient and good quality of care for the clinician.
- 48:58SPEAKER_01: So the patients need the will to be able to access services once you're tested.
- 49:04SPEAKER_01: Access and stay engaged in services.
- 49:07SPEAKER_01: And the will is not just about them being able to access the services, but also about the services being acceptable and adaptable to their needs, so that it is a service that they feel able to go to over and over again.
- 49:21SPEAKER_03: So, in one sentence each, um, what should clinicians take from Angelina's message?
- 49:26SPEAKER_03: I'll start with Tristan and then move to Lung Ha and then Lidegael.
- 49:32SPEAKER_04: Well, I know Angelina personally very well.
- 49:34SPEAKER_04: I'm very lucky to know Angelina, and I would say that the key message here is that Angelina really reminds us how important it is to be person-centered.
- 49:44SPEAKER_04: And I have to remind myself of that every day because again, I mentioned it earlier, but sometimes we make assumptions about people, but you need to meet them where they are.
- 49:52SPEAKER_04: And I think that's why a really important question in a consultation can just be the simple, what's the most important thing for you today?
- 50:00SPEAKER_04: And that gives people the space sometimes to bring something to the meeting that wasn't what you had in mind for the traditional medical consultation.
- 50:08SPEAKER_04: So, yeah, single sentence from Angelina for me is be person centred every time with every single person you interact with.
- 50:18SPEAKER_03: And Ling Hua, how about you?
- 50:21SPEAKER_05: Yeah, um I I I don't know I Andrew and uh I I I don't know her, yeah, but I I I do have one sentence uh to uh to to give her.
- 50:32SPEAKER_05: I think uh we can work together uh to fight with HIV and to to achieve good health.
- 50:39SPEAKER_05: Yeah, yeah, I think uh yeah, so we have a lot of uh just new um medicine and we can uh work together uh to to fight with HIV.
- 50:50SPEAKER_05: And I in I in my opinion, uh in the future we will uh just um uh completely cure HIV.
- 51:00SPEAKER_05: Yeah.
- 51:00unknown: Okay.
- 51:02SPEAKER_06: Thanks.
- 51:03SPEAKER_06: I'm also lucky to know Angelina, and it's a real pleasure.
- 51:06SPEAKER_06: Um she is uh inspiring to say the very least, but she also, to my mind, epitomizes 40 million individuals around the world who live with HIV every day.
- 51:18SPEAKER_06: And and you know, the the the we ask a lot, right?
- 51:23SPEAKER_06: They have to stay engaged and stay in treatment for the rest of their lives.
- 51:27SPEAKER_06: And I mean, you know, Tristan and and Lee have said this so beautifully that Dr.
- 51:32SPEAKER_06: Lee have said this so beautifully that we the best expert is the person sitting in front of us.
- 51:39SPEAKER_06: We think we're the experts, but actually they're the experts of their lives.
- 51:43SPEAKER_06: Um, and you know, in order for them to really derive the best benefit out of their care and treatment, we need to ensure that we provide the kind of care and treatment that is going to enable them to do that.
- 51:58SPEAKER_06: And um, I hope today's uh, you know, uh session has really given people new ideas of of how to go about that.
- 52:07SPEAKER_06: But again, thanks to wonderful advocates like Angelina, just to keep us focused and accountable in terms of what our role is.
- 52:16SPEAKER_03: Wonderful, so beautifully said.
- 52:17SPEAKER_03: I'm like, I want to meet Angelina.
- 52:19SPEAKER_03: She sounds she's so inspiring.
- 52:21SPEAKER_03: Um, so you know, her message is the reason why any of this discussion matters.
- 52:26SPEAKER_03: And so we want to make sure that we take her message and we translate it to action.
- 52:31SPEAKER_03: Um, and one way to do that is using SMART goals, so specific, measurable, attainable, relevant, and timely actions.
- 52:41SPEAKER_03: Um, and consider how you might apply these SMART goals in your practice.
- 52:46SPEAKER_03: So make patient counseling and share decision-making routine components of HIV care by identifying treatment priorities, concerns, and barriers, building interprofessional workflows that reflect locally available resources, and clearly defined roles for clinicians and nurses and pharmacists, community health workers, peer supporters, and navigators.
- 53:12SPEAKER_03: Also adapt treatment, service delivery plans, and digital tools to patient preferences, comorbidities, access barriers, clinic capacity, adherence, and engagement.
- 53:24SPEAKER_03: And then lastly, when considering long-acting injectable treatment, assess clinical appropriateness together with availability, affordability, appointment logistics, and whether the approach is acceptable and adaptable to the person's needs.
- 53:41SPEAKER_03: Thank you to our faculty for sharing their expertise and regional perspectives.
- 53:46SPEAKER_03: And thank you to our audience for your continued commitment to improving testing, linkage, and care for people living with HIV.